GLP-1 Drug Linked to Heart Benefits in High-Risk CVD Patients
The BMJ study followed nearly 53,000 patients and found 2.9% of Mounjaro users had major cardiovascular events versus 4.4% on sitagliptin.
- A new BMJ study found that Mounjaro, a GLP-1 receptor agonist also called tirzepatide, reduced heart attack risk by 33% in patients with type 2 diabetes, comparing nearly 53,000 patients against those taking sitagliptin.
- Mounjaro is a GLP-1 receptor agonist currently used on the NHS to treat type 2 diabetes and severe obesity; researchers selected sitagliptin as a neutral placebo proxy because prior studies showed it has no cardiovascular effect.
- At one year, Mounjaro users had a 2.9% risk of major cardiovascular events compared with 4.4% in the sitagliptin group, while the treatment prevented one hospital admission for infections for every 48 patients.
- "This study shows how trial-anchored evidence can estimate the expected cardiovascular benefit," said Nils Krüger, physician data scientist at Brigham and Women's Hospital, noting findings support integrating tirzepatide into clinical cardiovascular practice.
- Researchers acknowledged the observational study had a relatively short follow-up period, potentially underestimating long-term effects; authors concluded "The signal is compelling; the causal and clinical placement questions remain open.
13 Articles
13 Articles
A certain habit in middle age may predict an increased risk of cardiovascular disease.
Long-term diabetes medication adherence linked to lower heart attack and stroke risk
Type 2 diabetes is associated with an increased risk of heart disease. Many people with type 2 diabetes are prescribed blood sugar-lowering medication to reduce this risk. However, not everyone takes their medication consistently, and that inconsistency could leave them more exposed.
Tirzepatide lowers risk for cardiovascular events in real-world setting
Tirzepatide reduced risk for major adverse cardiovascular events among adults with type 2 diabetes and established atherosclerotic cardiovascular disease, according to real-world data published in The BMJ. As Healio previously reported, the SURPASS-CVOT trial found tirzepatide (Mounjaro, Eli Lilly) conferred a similar reduction in risk for CV events as dulaglutide (Trulicity, Eli Lilly) among
Coverage Details
Bias Distribution
- 84% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
